IRVINE, Calif., June 1, 2017 /PRNewswire/ -- EP Global Communications, Inc. (Public OTC: EPGL)
I had promised an update today on more than one topic. I decided rather than some boring formal report, I'd sit with you, the reader personally, as if we were together, talking over a drink. Also, I am doing this
I have long told shareholders that EPGL's IP and technologies would get attention by industry and media at some point and it might come unexpectedly. Just this situation came true recently when Agora Financial featured EPGL in its Defense Technology newsletter. As a result EPGL stock shot up to .055 cents recently and is now still at around .04 cents at this writing.
I learned of the Agora piece literally a day before it was published. Agora writer Kevin Massengill apparently recognized our tech and its potential for US Military applications and alerted their subscribers to this. After receiving some inquisitive emails from shareholders and associates about this rumored story about to break and the use of our technology photograph, I emailed Agora asking what was going on. I was informed via email that they were to publish a piece for their subscribers on EPGL technology after hours that Friday night.
As I had warned shareholders before that upward corrections can happen almost overnight and EPGL shot up 300% as a result of Agora's coverage on our technology and its potential. But because Agora's piece failed to get into detail of our IP portfolio, their subscribers got only half of the story. I hope Agora reads this and updates their people in coming days. Their people deserve the whole story.
As much as the Agora piece brought attention, it failed to point out something very significant for EPGL. The "Elastic Circuit" (US Patent No. 9538641 – Issued January 3, 2017). Few investors understand the Elastic Circuit patent and its significance. But the contact lens industry does!
EPGL has been as high as near 10 cents in recent years. However, since that time, we now have some 16 patents granted or pending in ophthalmic alone and among the granted is the Elastic Circuit. Also, since that time, a $300 billion dollar company acquired first right of purchase negotiations on our built technologies. We're presently at 4 cents per share with 16 patents pending domestic and internationally. I think we might correct to previous highs and beyond once the following information below is digested by Agora and the industry. Again, I am sounding the warning to not be surprised if it happens quickly.
Why does this matter to investors? Because smart contact lenses are coming very soon and it's going to be a massive business. Several manufacturers are vying to get into the game. Multi-billion dollar companies. EPGL beat a lot of them to the punch in technology and IP. The state-of-the-art is soft silicone hydrogel lenses, mass manufactured via injection mold. Millions and millions of contact lenses are manufactured every day in this way. A projected $15 billion dollar contact lens business in just 3 years from now. As smart, accommodative and augmented lenses take off in the near future, EPGL's Elastic Circuit US patent owns and protects the art of three-dimensional elastic circuitry specifically designed to accommodate medical device materials that swell in three-dimensions during the manufacturing processes. The biggest manufacturers of contact lenses are very aware of the significance and there's only so many ways to integrate electronics into silicone hydrogel lenses. This could potentially account for as much as 90% of future smart lenses manufactured in the world!
Besides the Elastic Circuit patent, EPGL has even more patents that have equal importance if not greater to the field of contact lenses. InWith Corporation recognizes this and is now aggressively presenting to top VC firms as we speak about the major capital raise. InWith Corporation wants to be the leading manufacturer of EPGL technologies and smart lenses. The private company has engaged a top silicon valley law firm and intends to make an offer to acquire EPGL tech and/or shareholders. As of today May 31, many options are being considered and terms are being discussed with one or more capital firms. As you know, these things can develop rapidly and I intend to keep everyone informed.
In summary, as the Agora Financial experience teaches us, (300%+ rocket in just a few days) EPGL can correct upward quickly. I hope that the writers at Agora Financial will make their people aware of this PR in coming days because they frankly missed a large part of EPGL. I believe they sold the EPGL potential very short to their readers. But, I can't expect them to know everything I know.
I am warning once again that based on what I know, it is inevitable that EPGL technologies will be gaining even more attention as more financial people like Agora and other media become aware of our IP. If this is true, it makes now the time to be into EPGL at this level. My opinion is that we will surpass our previous highs because as we sit right now, we have much more going now than we did when we hit those those previous highs. It is common sense that we could be in for a retrace to record highs and it can happen very fast as you know. –Michael Hayes, President and Co-Inventor
About EP Global Communications, Inc.
EPGL has several patents pending in the growing new field of electronic vision correction, enhancement and augmentation. Specifically, the Company has developed proven methods for successful integration of electronic circuitry into real silicone hydrogel contact lenses during the manufacturing process.
EP Global Communications, Inc. is an advanced technology research and development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/agora-financial-features-epgl-but-missed-the-elastic-circuit-patent-300466894.html
SOURCE EP Global Communications, Inc.
Subscribe to our Free Newsletters!
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...View All